Missed GME or NVDA? Donโt Miss the Next One.โ
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Talphera Inc. (TLPH) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic
$0.49
+0.01 (2.08%)Did TLPH Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if AcelRx is one of their latest high-conviction picks.
Based on our analysis of 3 Wall Street analysts, TLPH has a bullish consensus with a median price target of $3.25 (ranging from $3.00 to $3.50). Currently trading at $0.49, the median forecast implies a 563.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jason McCarthy at Maxim Group, suggesting a 512.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for TLPH.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Apr 1, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
Jan 21, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
Aug 16, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
May 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
May 6, 2024 | Maxim Group | Jason McCarthy | Buy | Initiates | $3.00 |
Mar 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
Jan 22, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $6.00 |
Dec 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
Oct 2, 2023 | Alliance Global Partners | Buy | Initiates | $0.00 | |
Sep 25, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
Aug 18, 2023 | HC Wainwright & Co. | Buy | Upgrade | $0.00 |
The following stocks are similar to AcelRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Talphera Inc. has a market capitalization of $10.05M with a P/E ratio of -1.0x. The company generates $27,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -10,800.0% and return on equity of -106.8%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Provides renewable energy solutions through wind and solar.
Talphera Inc. generates revenue by designing, developing, and deploying scalable energy systems for both commercial and residential markets. The company leverages advancements in energy efficiency and storage to enhance its offerings and supports infrastructure projects that modernize energy grids, which further contributes to its income streams.
Talphera Inc. is recognized as a significant player in the renewable energy sector, focusing on reducing carbon footprints and promoting sustainability. The company's efforts are aligned with global trends towards green energy initiatives, positioning it as a key contributor to environmental sustainability and economic growth.
Healthcare
Drug Manufacturers - Specialty & Generic
13
Mr. Vincent J. Angotti
United States
2011
Talphera, Inc. (NASDAQ:TLPH) will hold its Q1 2025 earnings conference call on May 14, 2025, at 4:30 PM ET. Participants include CFO Raffi Asadorian and CEO Vincent Angotti.
Talphera's Q1 2025 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
Talphera, Inc. reported $9.8 million in cash and investments as of March 31, 2025, following a private placement. Three clinical study sites are active, with five more expected by mid-year.
Talphera's financial health, with $9.8 million in cash and active clinical trials, indicates growth potential and ongoing investment in development, crucial for future profitability and stock performance.
Talphera, Inc. (Nasdaq: TLPH) will release its Q1 2025 financial results on May 14, 2025, after market close, followed by a webcast and conference call at 4:30 p.m.
Talphera's upcoming financial results release and conference call could influence stock performance and investor sentiment, reflecting the company's growth and market position.
Talphera (TLPH) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, potentially leading to higher stock performance.
Talphera's upgrade to a Zacks Rank #1 indicates strong earnings potential, suggesting upward momentum in its stock price, which can attract more investors and drive demand.
Talphera (TLPH) has received a Zacks Rank #2 (Buy) upgrade, indicating improved earnings outlook and potential for stock price increase.
Talphera's upgrade to a Zacks Rank #2 indicates increased confidence in its earnings potential, likely boosting investor sentiment and driving the stock price upward.
Talphera, Inc. (NASDAQ:TLPH) will host its Q4 2024 earnings conference call on March 31, 2025, at 4:30 PM ET, featuring key executives.
Talphera's Q4 earnings call indicates upcoming financial performance insights, crucial for evaluating the company's growth potential and investment viability.
Based on our analysis of 3 Wall Street analysts, Talphera Inc. (TLPH) has a median price target of $3.25. The highest price target is $3.50 and the lowest is $3.00.
According to current analyst ratings, TLPH has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.49. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict TLPH stock could reach $3.25 in the next 12 months. This represents a 563.3% increase from the current price of $0.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
Talphera Inc. generates revenue by designing, developing, and deploying scalable energy systems for both commercial and residential markets. The company leverages advancements in energy efficiency and storage to enhance its offerings and supports infrastructure projects that modernize energy grids, which further contributes to its income streams.
The highest price target for TLPH is $3.50 from at , which represents a 614.3% increase from the current price of $0.49.
The lowest price target for TLPH is $3.00 from Jason McCarthy at Maxim Group, which represents a 512.2% increase from the current price of $0.49.
The overall analyst consensus for TLPH is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.25.
Stock price projections, including those for Talphera Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.